Important note

This AI stock analysis for Amwell is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Amwell - AI Stock Analysis

Analysis generated March 23, 2025

Amwell, also known as American Well Corporation, is a prominent player in the rapidly growing telehealth and telemedicine industry. Founded in 2006, Amwell provides healthcare services through a digital delivery platform that connects patients with doctors and other healthcare providers over the internet. The company offers a broad range of services, including urgent care, behavioral health, pediatrics, and chronic care management, aiming to make healthcare more accessible and convenient.

Fundamental Analysis

The fundamental analysis of Amwell indicates mixed signals. Amwell reported a revenue of $64M for the last quarter, which represents a decrease of 3.50% compared to the preceding quarter. This could raise concerns about the short-term revenue trends. However, compared to the same quarter last year, revenue has increased by 2.99%, initiating a positive perspective on yearly growth.

Net income for the last quarter was $43M, demonstrating an increase of 12.93% from the previous quarter. This signal of positive growth extends to a year-over-year perspective as well, showing a 68.14% increase compared to the same quarter last year.

Adjusted EBITDA for the last quarter was reported at $39M. This is an 11.56% increase compared to the prior quarter, and an impressive 71.09% rise relative to the same period last year. These figures reveal solid operational efficiency and an improved earnings profile.

However, it is worth noting that there has been insider selling by several company leaders over the past couple of months. Such activities by insiders may be perceived as a bearish signal, raising caution among potential investors.

Technical Analysis

The current stock price of Amwell stands at $7.81. Over the past month, the stock has seen a significant decrease of 33.48%, raising short-term concerns. Long-term indicators also suggest caution, with the price dropping by 55.68% over the past year.

Amwell’s short-term moving average (SMA10) is $7.91, compared to a previous SMA10 of $7.92. This marginal decline reinforces the bearish trend observed in the stock price. Additionally, the Relative Strength Index (RSI) is at 24.2, which might imply that the stock is currently oversold and could potentially exhibit a bullish reversal.

Alternative Data Analysis

Alternative data reveals mixed insights about Amwell’s performance and market perception. Job postings have seen a 46% increase, indicating potential growth and expansion within the company. Nevertheless, only 9% of employees have a positive business outlook, a figure that has decreased by 31% in recent months, signaling internal challenges and concerns.

Analyzing customer metrics, Amwell’s website traffic has decreased substantially, with visitor counts down by 40% over the past couple of months. Daily mobile app downloads have also reduced by 9%, pointing to a possible decline in user engagement and customer acquisition.

On the social media front, Amwell holds 8,800 Instagram followers and 9,800 Twitter followers, with follower counts either stagnant or declining slightly. This suggests a possible wane in public interest and engagement with the brand.

AltIndex’s AI, which leverages various data points to predict stock price movement, scores Amwell at 12, indicating a strong sell signal.

Conclusion

In summary, Amwell presents a complex investment profile. The company shows positive year-over-year growth in revenue, net income, and EBITDA, highlighting operational efficiency and resilience. Nonetheless, recent revenue decline and insider selling are red flags.

Technical indicators are currently bearish, with the stock showing significant declines in both the short and long term. However, the low RSI suggests potential oversold conditions which might lead to a bullish reversal.

Alternative data further clouds the picture, with decreasing web traffic, app downloads, and social media engagement offsetting the positive signal of increased job postings.

Considering the mixed signals from fundamental, technical, and alternative data analyses, the recommendation is to approach Amwell with caution. The stock may not be a strong buy at this juncture, and potential investors should closely monitor upcoming earnings reports, insider activity, and market conditions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.